Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor - PubMed (original) (raw)
Review
Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor
Michael Ploug. Curr Pharm Des. 2003.
Abstract
Degradation of the extracellular matrix plays an important role in a number of normal and pathological conditions involving active tissue remodeling such as postlactational mammary gland involution, wound healing and tumor invasion and metastasis. The expression of a high-affinity, glycolipid-anchored receptor for the urokinase-type plasminogen activator (uPAR) is often up-regulated during such tissue remodeling events. uPAR may, therefore, in cooperation with various matrix metalloproteases, serve to facilitate the proteolytic breakdown of the extracellular matrix via uPA catalyzed plasminogen activation at the foci where cellular invasion occurs. Consistent with such a role for uPAR in pericellular proteolysis is the observation that the membrane assembly of both plasminogen, via its lysine binding-sites, and of pro-uPA, via its tight binding to uPAR, is required to favor and confine plasminogen activation potential in proximity of the cell surface. This review will focus on molecular properties of uPAR including its membrane attachment by glycosyl-phosphatidylinositol, its multidomain structure and its relationship to the Ly-6/uPAR/alpha-neurotoxin protein domain family. Furthermore a mapping of the functional epitopes for uPA binding as well as a competitive peptide antagonist of the uPA-uPAR interaction will be discussed.
Similar articles
- Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy.
Ploug M, Gårdsvoll H, Jørgensen TJ, Lønborg Hansen L, Danø K. Ploug M, et al. Biochem Soc Trans. 2002 Apr;30(2):177-83. Biochem Soc Trans. 2002. PMID: 12023847 Review. - Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V, Bürgle M, de Prada NA, Schmiedeberg N, Riemer C, Schroeck F, Kellermann J, Degitz K, Wilhelm OG, Schmitt M, Kessler H. Magdolen V, et al. Biol Chem. 2001 Aug;382(8):1197-205. doi: 10.1515/BC.2001.150. Biol Chem. 2001. PMID: 11592401 - Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
Quax PH, Grimbergen JM, Lansink M, Bakker AH, Blatter MC, Belin D, van Hinsbergh VW, Verheijen JH. Quax PH, et al. Arterioscler Thromb Vasc Biol. 1998 May;18(5):693-701. doi: 10.1161/01.atv.18.5.693. Arterioscler Thromb Vasc Biol. 1998. PMID: 9598826 - A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor.
Rettenberger P, Wilhelm O, Oi H, Weidle UH, Goretzki L, Koppitz M, Lottspeich F, König B, Pessara U, Kramer MD, et al. Rettenberger P, et al. Biol Chem Hoppe Seyler. 1995 Oct;376(10):587-94. doi: 10.1515/bchm3.1995.376.10.587. Biol Chem Hoppe Seyler. 1995. PMID: 8590627 - Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T, Behrendt N, Ploug M. Plesner T, et al. Stem Cells. 1997;15(6):398-408. doi: 10.1002/stem.150398. Stem Cells. 1997. PMID: 9402652 Review.
Cited by
- circPSD3 is a promising inhibitor of uPA system to inhibit vascular invasion and metastasis in hepatocellular carcinoma.
Xu L, Wang P, Li L, Li L, Huang Y, Zhang Y, Zheng X, Yi P, Zhang M, Xu M. Xu L, et al. Mol Cancer. 2023 Oct 26;22(1):174. doi: 10.1186/s12943-023-01882-z. Mol Cancer. 2023. PMID: 37884951 Free PMC article. - Therapeutic Strategies Targeting Urokinase and Its Receptor in Cancer.
Masucci MT, Minopoli M, Di Carluccio G, Motti ML, Carriero MV. Masucci MT, et al. Cancers (Basel). 2022 Jan 19;14(3):498. doi: 10.3390/cancers14030498. Cancers (Basel). 2022. PMID: 35158766 Free PMC article. Review. - The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and Opportunities.
Metrangolo V, Ploug M, Engelholm LH. Metrangolo V, et al. Cancers (Basel). 2021 Oct 27;13(21):5376. doi: 10.3390/cancers13215376. Cancers (Basel). 2021. PMID: 34771541 Free PMC article. Review. - Evolution and Medical Significance of LU Domain-Containing Proteins.
Leth JM, Leth-Espensen KZ, Kristensen KK, Kumari A, Lund Winther AM, Young SG, Ploug M. Leth JM, et al. Int J Mol Sci. 2019 Jun 5;20(11):2760. doi: 10.3390/ijms20112760. Int J Mol Sci. 2019. PMID: 31195646 Free PMC article. Review. - Be Active or Not: the Relative Contribution of Active and Passive Tumor Targeting of Nanomaterials.
Li R, Zheng K, Yuan C, Chen Z, Huang M. Li R, et al. Nanotheranostics. 2017 Jul 11;1(4):346-357. doi: 10.7150/ntno.19380. eCollection 2017. Nanotheranostics. 2017. PMID: 29071198 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous